Praxis Precision Medicines review

The short version

Praxis works on brain diseases caused by an imbalance in electrical signals between nerve cells. It has no medicine on the market yet, but it could have two within weeks of each other: relutrigine for severe childhood epilepsy, with an FDA decision on 27 December 2026, and ulixacaltamide for essential tremor, on 29 January 2027. Its shares trade near $280, far above their 52-week low of about $154 (Praxis Q2 2026 results).

The latest FDA decision: delayed

On 29 June 2026 Praxis said the FDA had moved its decision on relutrigine from 27 September to 27 December, after Praxis sent extra analyses. No new trials were requested, and the FDA later reported no major safety or efficacy concerns at its mid-review check (NeurologyLive). The shares rose about 2% around the news, as our FDA Decision Calendar shows.

What it makes

Relutrigine calms overactive nerve cells in children with rare genetic epilepsies, in which seizures start early and damage development. Ulixacaltamide targets the brain circuits behind essential tremor. Its Phase 3 programme enrolled over 700 people, and the FDA gave it Breakthrough status in December 2025. Vormatrigine is an epilepsy pill, and elsunersen is a genetic medicine for one form of childhood epilepsy.

The setback so far came in June 2026: the POWER1 trial of vormatrigine, in patients with very hard-to-treat epilepsy, missed its main goal of fewer seizures at week 12. It did show more patients with at least 50% fewer seizures, and Praxis plans to continue with two more trials.

Is it really new?

Yes, in most cases. Essential tremor affects millions of Americans and has seen no new approved drug for decades. Ulixacaltamide would be a true step forward if it wins approval. Relutrigine would be among the first medicines designed for these specific genetic epilepsies.

The competition

In tremor the competition is old and cheap: propranolol and primidone, which many patients stop taking. Praxis’s challenge is getting doctors to prescribe a new, more expensive drug. In focal seizures, Xenon’s azetukalner and Xcopri are strong rivals. In childhood epilepsy, others treat different diseases, such as Dravet syndrome.

Money

Praxis lost $83.7 million in Q2 2026, and it held about $1.4 billion in cash on 30 June, enough into 2028. It raised money in January 2026, so it does not need to do so soon, and it has the resources to launch on its own.

Risks

• Two decisions at once. A rejection of either drug would hurt, especially ulixacaltamide, which carries most of the company’s value.
• Side effects. Dizziness and brain fog in tremor patients could limit use, and the label will matter.
• First launch. Praxis has never sold a drug, and the tremor market needs a big commercial effort.
• High expectations. The shares already price in a good outcome.

Our take

Praxis looks well prepared: plenty of cash, a clean review so far and two chances at a first approval. The POWER1 miss is a reminder that not every program works. The January decision on ulixacaltamide matters most, because essential tremor is by far the largest market. If both go well, Praxis becomes a commercial company in early 2027.